Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study

Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study

Background and Aim: Alzheimer disease (AD) is the most common cause of dementia. Currently, there is no disease-modifying therapy for AD. We aimed to evaluate the long-term efficacy and safety of MLC601 in the treatment of AD. Methods: In this open-label extension study, patients with mild to modera...

Full description

Bibliographic Details
Main Authors: Hossein Pakdaman, Koroush Gharagozli, Mehdi Abbasi, Ali Sobhanian, Ali Bakhshandehpour, Farzad Ashrafi, Mitra Khalilzad, Ali Amini Harandi
Format: Article
Language:English
Published: Karger Publishers 2018-04-01
Series:Dementia and Geriatric Cognitive Disorders Extra
Subjects:
Alzheimer disease
MLC601
Follow-up study
Safety
Online Access:https://www.karger.com/Article/FullText/488482

Internet

https://www.karger.com/Article/FullText/488482

Similar Items